KW Wealth Management LLC Makes New $963,000 Investment in AbbVie Inc. $ABBV

KW Wealth Management LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,158 shares of the company’s stock, valued at approximately $963,000. AbbVie makes up 1.6% of KW Wealth Management LLC’s investment portfolio, making the stock its 18th biggest position.

Several other large investors also recently modified their holdings of ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie in the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie during the second quarter worth $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at $39,000. 70.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent analyst reports. Morgan Stanley increased their target price on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Citigroup dropped their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a report on Monday, November 3rd. UBS Group boosted their target price on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Stock Performance

Shares of AbbVie stock opened at $230.07 on Monday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The firm has a 50 day simple moving average of $226.73 and a 200 day simple moving average of $212.72. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm has a market cap of $406.63 billion, a P/E ratio of 174.30, a P/E/G ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio is 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.